

Progress in NEUROBIOLOGY

VOLUME 95, ISSUE 4

December 2011

CONTENTS

Special Issue: Biological Markers for Neurodegenerative Diseases

Introduction

Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention

JOHN Q. TROJANOWSKI AND HARALD HAMPEL

491

Perspectives of worldwide translational biomarker research in neurodegenerative diseases

PIERLUIGI NICOTERA AND HARALD HAMPEL

496

Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements

KARL BROICH, MARCO WEIERGRÄBER AND HARALD HAMPEL

498

The role of genetics for biomarker development in neurodegeneration

LARS BERTRAM AND HARALD HAMPEL

501

Functional biomarkers for neurodegenerative disorders based on the network paradigm

BARRY HORWITZ AND JAMES B. ROWE

505

Biomarkers and evolution in Alzheimer disease

STANLEY I. RAPOPORT AND PETER T. NELSON

510

Neuroimaging and the question of neurodegeneration in schizophrenia

ANDREAS MEYER-LINDENBERG

514

Ethical considerations of biomarker use in neurodegenerative diseases – A case study of Alzheimer's disease

DAVID PRVULOVIC AND HARALD HAMPEL

517

(Contents continued on bm V)

Available online at www.sciencedirect.com

SciVerse ScienceDirect

Indexed Abstracted in: Biosis Data, Chem Abstr. Curr. Cont / Life Sci, CABS, Excerpt Med Curr Cont Ind Sci Rev. Curr Cont ISI BIOMED Database, MEDLINE, Curr Cont Sci Cit Ind, Curr Cont SCISEARCH Data, Ind Med, PsycINFO. Res Alert. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.






0301-0082(201112)95:4;1-0



PROGRESS IN NEUROBIOLOGY

Special Issue

Biological Markers for Neurodegenerative Diseases



Guest Editors

Harald Hampel and John Q. Trojanowski

(Continued from inside back cover)

Review Articles

Biomarker-based dissection of neurodegenerative diseases

BOB OLSSON, HENRIK ZETTERBERG, HARALD HAMPEL AND KAJ BLENNOW

520

Staging Alzheimer's disease progression with multimodality neuroimaging

MICHAEL EWERS, GIOVANNI B. FRISONI, STEFAN J. TEIPEL, LEA T. GRINBERG, EDSON AMARO JR., HELMUT HEINSEN, PAUL M. THOMPSON AND HARALD HAMPEL

535

Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression

STEFAN J. TEIPEL, RALPH BUCHERT, JOHANNES THOME, HARALD HAMPEL AND JENS PAHNKE

547

Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease

DAVID PRVULOVIC, ARUN L.W. BOKDE, FRANK FALTRACO AND HARALD HAMPEL

557

Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease

HARALD HAMPEL, DAVID PRVULOVIC, STEFAN J. TEIPEL AND ARUN L.W. BOKDE

570

Biomarkers for Alzheimer's disease therapeutic trials

HARALD HAMPEL, GORDON WILCOCK, SANDRINE ANDRIEU, PAUL AISEN, KAJ BLENNOW, K. BROICH, MARIA CARRILLO, NICK C. FOX, GIOVANNI B. FRISONI, MARIA ISAAC, SIMON LOVESTONE, AGNETA NORDBERG, DAVID PRVULOVIC, CHRISTINA SAMPAIO, PHILIP SCHELTENS, MICHAEL WEINER, BENGT WINBLAD, NICOLA COLEY, BRUNO VELLAS AND FOR THE OXFORD TASK FORCE GROUP

579

Prevention trials in Alzheimer's disease: An EU-US task force report

BRUNO VELLAS, PAUL S. AISEN, CRISTINA SAMPAIO, MARIA CARRILLO, PHILIP SCHELTENS, BRUNO SCHERRER, GIOVANNI B. FRISONI, MICHAEL WEINER, LON SCHNEIDER, SERGE GAUTHIER, CHRISTINE C. GISPEN-DE WIED, SUZANNE HENDRIX, HOWARD FELDMAN, JESSE CEDARBAUM, RONALD PETERSEN, ERIC SIEMERS, SANDRINE ANDRIEU, DAVID PRVULOVIC, JACQUES TOUCHON AND HARALD HAMPEL

594

Biomarkers of Parkinson's disease and Dementia with Lewy bodies

CLAIRE HENCHCLIFFE, RICHARD DODEL AND M. FLINT BEAL

601

Imaging biomarkers in Parkinson's disease

DAVID J. BROOKS AND NICOLA PAVESE

614

The Parkinson Progression Marker Initiative (PPMI)

THE PARKINSON PROGRESSION MARKER INITIATIVE

629

Biomarkers in frontotemporal lobar degenerations—Progress and challenges

WILLIAM T. HU, JOHN Q. TROJANOWSKI AND LESLIE M. SHAW

636

On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia

F. GESER, D. PRVULOVIC, L. O'DWYER, O. HARDIMAN, P. BEDE, A.L.W. BOKDE, J.Q. TROJANOWSKI AND H.J. HAMPEL

649

The ALS/PDC syndrome of Guam: Potential biomarkers for an enigmatic disorder

PATRICK L. MCGEER AND JOHN C. STEELE

663

Development of biomarkers for multiple sclerosis as a neurodegenerative disorder

ULF ZIEMANN, MATHIAS WAHL, ELKE HATTINGEN AND HAYRETTIN TUMANI

670

Discovery and development of integrative biological markers for schizophrenia

VIOLA OERTEL-KNÖCHEL, ROBERT A. BITTNER, CHRISTIAN KNÖCHEL, DAVID PRVULOVIC AND HARALD HAMPEL

686

Biomarkers for major depression and its delineation from neurodegenerative disorders

BARBARA SCHNEIDER, DAVID PRVULOVIC, VIOLA OERTEL-KNÖCHEL, CHRISTIAN KNÖCHEL, BRITTA REINKE, MARTIN GREXA, BERNHARD WEBER AND HARALD HAMPEL

703

The future of Alzheimer's disease: The next 10 years

HARALD HAMPEL, DAVID PRVULOVIC, STEFAN TEIPEL, FRANK JESSEN, CHRISTIAN LUCKHAUS, LUTZ FRÖLICH, MATTHIAS W. RIEPE, RICHARD DODEL, THOMAS LEYHE, LARS BERTRAM, WOLFGANG HOFFMANN AND FRANK FALTRACO

718